Sara Giordano1, Elizabeth Garrett-Mayer1, Navdha Mittal2, Kristin Smith3, Lee Shulman4, Carolyn Passaglia5, William Gradishar5, Mary Ellen Pavone3. 1. 1 Medical University of South Carolina , Hollings Cancer Center, Charleston, South Carolina. 2. 2 AbbVie , Pharmaceutical Research and Development, Chicago, Illinois. 3. 3 Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine , Chicago, Illinois. 4. 4 Department of Obstetrics and Gynecology-Clinical Genetics, Northwestern University Feinberg School of Medicine , Chicago, Illinois. 5. 5 Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine , Chicago, Illinois.
Abstract
PURPOSE: Mutations in the BRCA1/2 genes are associated with breast and ovarian cancer susceptibility. Recent studies have suggested that the BRCA mutation might be associated with occult primary ovarian insufficiency. To evaluate fertility, several studies have validated anti-Mullerian hormone (AMH) as a direct biomarker for ovarian aging and it is considered a quantitative marker of ovarian reserve. We hypothesize that BRCA1 gene mutations will be negatively associated with AMH levels. METHODS: We evaluated 124 women aged 18-45 years participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program. Patients with a history of cancer, ovarian surgery, or exposure to chemotherapy were excluded. Linear and logistic regression modeling were performed to evaluate the association between AMH levels, age, and BRCA1 mutation. In logistic models, the outcome 'low AMH' was defined as AMH <0.05 ng/mL. Logistic regression models were used to adjust for other factors, including body mass index (BMI), duration of birth control (BC), smoking, gravidity, and parity. RESULTS: Women with the BRCA1 mutation had a significant decline in AMH with age (p = 0.0011). BRCA1-positive women >35 years had 10 times the odds of a low AMH (<0.5 ng/mL) compared with women ≤35 years. With adjustment for BMI, duration of BC, smoking, gravidity, parity, and age >35, BRCA1 was still strongly associated with a low AMH (p = 0.037). CONCLUSION: Women >35 with the BRCA1 mutation have a lower AMH, and hence ovarian reserve, than women without a BRCA mutation. Therefore, young adults with the BRCA1 mutation should be counseled regarding this potential decrease in ovarian reserve.
PURPOSE: Mutations in the BRCA1/2 genes are associated with breast and ovarian cancer susceptibility. Recent studies have suggested that the BRCA mutation might be associated with occult primary ovarian insufficiency. To evaluate fertility, several studies have validated anti-Mullerian hormone (AMH) as a direct biomarker for ovarian aging and it is considered a quantitative marker of ovarian reserve. We hypothesize that BRCA1 gene mutations will be negatively associated with AMH levels. METHODS: We evaluated 124 women aged 18-45 years participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program. Patients with a history of cancer, ovarian surgery, or exposure to chemotherapy were excluded. Linear and logistic regression modeling were performed to evaluate the association between AMH levels, age, and BRCA1 mutation. In logistic models, the outcome 'low AMH' was defined as AMH <0.05 ng/mL. Logistic regression models were used to adjust for other factors, including body mass index (BMI), duration of birth control (BC), smoking, gravidity, and parity. RESULTS:Women with the BRCA1 mutation had a significant decline in AMH with age (p = 0.0011). BRCA1-positive women >35 years had 10 times the odds of a low AMH (<0.5 ng/mL) compared with women ≤35 years. With adjustment for BMI, duration of BC, smoking, gravidity, parity, and age >35, BRCA1 was still strongly associated with a low AMH (p = 0.037). CONCLUSION:Women >35 with the BRCA1 mutation have a lower AMH, and hence ovarian reserve, than women without a BRCA mutation. Therefore, young adults with the BRCA1 mutation should be counseled regarding this potential decrease in ovarian reserve.
Authors: I A J van Rooij; F J M Broekmans; E R te Velde; B C J M Fauser; L F J M M Bancsi; F H de Jong; A P N Themmen Journal: Hum Reprod Date: 2002-12 Impact factor: 6.918
Authors: K Birch Petersen; H W Hvidman; J L Forman; A Pinborg; E C Larsen; K T Macklon; R Sylvest; A Nyboe Andersen Journal: Hum Reprod Date: 2015-08-25 Impact factor: 6.918
Authors: J van Disseldorp; M J Faddy; A P N Themmen; F H de Jong; P H M Peeters; Y T van der Schouw; F J M Broekmans Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: Annemarie de Vet; Joop S E Laven; Frank H de Jong; Axel P N Themmen; Bart C J M Fauser Journal: Fertil Steril Date: 2002-02 Impact factor: 7.329
Authors: Ellen W Freeman; Clarisa R Gracia; Mary D Sammel; Hui Lin; Lony Chong-Leong Lim; Jerome F Strauss Journal: Fertil Steril Date: 2006-11-15 Impact factor: 7.329
Authors: J Chen; D P Silver; D Walpita; S B Cantor; A F Gazdar; G Tomlinson; F J Couch; B L Weber; T Ashley; D M Livingston; R Scully Journal: Mol Cell Date: 1998-09 Impact factor: 17.970
Authors: Xiaohong R Yang; Beena C R Devi; Hyuna Sung; Jennifer Guida; Eliseos J Mucaki; Yanzi Xiao; Ana Best; Lisa Garland; Yi Xie; Nan Hu; Maria Rodriguez-Herrera; Chaoyu Wang; Kristine Jones; Wen Luo; Belynda Hicks; Tieng Swee Tang; Karobi Moitra; Peter K Rogan; Michael Dean Journal: Breast Cancer Res Treat Date: 2017-06-29 Impact factor: 4.872
Authors: Drechsel Katja C E; van Tilborg Theodora C; Eijkemans Marinus J C; Lentjes Eef G W M; Homminga Irene; Goddijn Mariette; van Golde Ron J T; Verpoest Willem; Lichtenbelt Klaske D; Broekmans Frank J M; Bos Anna M E Journal: Reprod Sci Date: 2022-06-15 Impact factor: 3.060
Authors: Lisa M Pastore; Mindy S Christianson; James Stelling; William G Kearns; James H Segars Journal: J Assist Reprod Genet Date: 2017-10-02 Impact factor: 3.412
Authors: Christina N Cordeiro Mitchell; Bailey McGuinness; Eliana Fine; William G Kearns; Mindy S Christianson; James Segars; Lisa M Pastore Journal: J Assist Reprod Genet Date: 2020-03-24 Impact factor: 3.412